Defining the Temporal Evolution of Gut Dysbiosis and Inflammatory Responses Leading to Hepatocellular Carcinoma in Mdr2 -/- Mouse Model

Overview

Journal BMC Microbiol

Publisher Biomed Central

Specialty Microbiology

Date 2021 Apr 16

PMID 33858327

Citations 9

Authors

J Behary

A E Raposo

N M L Amorim

H Zheng

L Gong

E McGovern

J Chen

K Liu

J Beretov

C Theocharous

M T Jackson

J Seet-Lee

G W McCaughan

E M El-Omar

A Zekry

Affiliations

Soon will be listed here.

Abstract

Background: Emerging evidence implicates the gut microbiome in liver inflammation and hepatocellular carcinoma (HCC) development. We aimed to characterize the temporal evolution of gut dysbiosis, in relation to the phenotype of systemic and hepatic inflammatory responses leading to HCC development. In the present study, Mdr2 -/- mice were used as a model of inflammation-based HCC. Gut microbiome composition and function, in addition to serum LPS, serum cytokines/chemokines and intrahepatic inflammatory genes were measured throughout the course of liver injury until HCC development.

Results: Early stages of liver injury, inflammation and cirrhosis, were characterized by dysbiosis. Microbiome functional pathways pertaining to gut barrier dysfunction were enriched during the initial phase of liver inflammation and cirrhosis, whilst those supporting lipopolysaccharide (LPS) biosynthesis increased as cirrhosis and HCC ensued. In parallel, serum LPS progressively increased during the course of liver injury, corresponding to a shift towards a systemic Th1/Th17 proinflammatory phenotype. Alongside, the intrahepatic inflammatory gene profile transitioned from a proinflammatory phenotype in the initial phases of liver injury to an immunosuppressed one in HCC. In established HCC, a switch in microbiome function from carbohydrate to amino acid metabolism occurred.

Conclusion: In Mdr2 -/- mice, dysbiosis precedes HCC development, with temporal evolution of microbiome function to support gut barrier dysfunction, LPS biosynthesis, and redirection of energy source utilization. A corresponding shift in systemic and intrahepatic inflammatory responses occurred supporting HCC development. These findings support the notion that gut based therapeutic interventions could be beneficial early in the course of liver disease to halt HCC development.

Citing Articles

Big lessons from the little in hepatocellular carcinoma.

Yang Y, Shi X Front Immunol. 2025; 16:1524563.

PMID: 40028328 PMC: 11868108. DOI: 10.3389/fimmu.2025.1524563.

The emerging role of bacterial extracellular vesicles in human cancers.

Liang A, Korani L, Yeung C, Tey S, Yam J J Extracell Vesicles. 2024; 13(10):e12521.

PMID: 39377479 PMC: 11460218. DOI: 10.1002/jev2.12521.

Diagnostic and Prognostic Value of IL-10, FABP2 and LPS Levels in HCC Patients.

Morkunas E, Vaitkeviciute E, Varkalaite G, Pilvinis V, Skieceviciene J, Kupcinskas J Medicina (Kaunas). 2023; 59(12).

PMID: 38138294 PMC: 10744942. DOI: 10.3390/medicina59122191.

Potential tactics with certain gut microbiota for the treatment of unresectable hepatocellular carcinoma.

Yoshikawa S, Taniguchi K, Sawamura H, Ikeda Y, Asai T, Tsuji A Explor Target Antitumor Ther. 2023; 4(4):556-568.

PMID: 37720344 PMC: 10501893. DOI: 10.37349/etat.2023.00152.

Unveiling the complex relationship between gut microbiota and liver cancer: opportunities for novel therapeutic interventions.

Rajapakse J, Khatiwada S, Akon A, Yu K, Shen S, Zekry A Gut Microbes. 2023; 15(2):2240031.

PMID: 37615334 PMC: 10454000. DOI: 10.1080/19490976.2023.2240031.

References

Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu M, Allen C . The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol. 2017; 3(12):1683-1691. PMC: 5824275. DOI: 10.1001/jamaoncol.2017.3055. View

Ma C, Han M, Heinrich B, Fu Q, Zhang Q, Sandhu M . Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science. 2018; 360(6391). PMC: 6407885. DOI: 10.1126/science.aan5931. View

Katzenellenbogen M, Mizrahi L, Pappo O, Klopstock N, Olam D, Jacob-Hirsch J . Molecular mechanisms of liver carcinogenesis in the mdr2-knockout mice. Mol Cancer Res. 2007; 5(11):1159-70. DOI: 10.1158/1541-7786.MCR-07-0172. View

Callahan B, McMurdie P, Rosen M, Han A, Johnson A, Holmes S . DADA2: High-resolution sample inference from Illumina amplicon data. Nat Methods. 2016; 13(7):581-3. PMC: 4927377. DOI: 10.1038/nmeth.3869. View

Nomura F, Akashi S, Sakao Y, Sato S, Kawai T, Matsumoto M . Cutting edge: endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface toll-like receptor 4 expression. J Immunol. 2000; 164(7):3476-9. DOI: 10.4049/jimmunol.164.7.3476. View

Saltzman E, Palacios T, Thomsen M, Vitetta L . Intestinal Microbiome Shifts, Dysbiosis, Inflammation, and Non-alcoholic Fatty Liver Disease. Front Microbiol. 2018; 9:61. PMC: 5797576. DOI: 10.3389/fmicb.2018.00061. View

Ivashkiv L . The hypoxia-lactate axis tempers inflammation. Nat Rev Immunol. 2019; 20(2):85-86. PMC: 7021227. DOI: 10.1038/s41577-019-0259-8. View

Benson A, Kelly S, Legge R, Ma F, Low S, Kim J . Individuality in gut microbiota composition is a complex polygenic trait shaped by multiple environmental and host genetic factors. Proc Natl Acad Sci U S A. 2010; 107(44):18933-8. PMC: 2973891. DOI: 10.1073/pnas.1007028107. View

Jiang W, Wu N, Wang X, Chi Y, Zhang Y, Qiu X . Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep. 2015; 5:8096. PMC: 4314632. DOI: 10.1038/srep08096. View

10.

Yoshimoto S, Loo T, Atarashi K, Kanda H, Sato S, Oyadomari S . Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature. 2013; 499(7456):97-101. DOI: 10.1038/nature12347. View

11.

Zhou A, Tang L, Zeng S, Lei Y, Yang S, Tang B . Gut microbiota: A new piece in understanding hepatocarcinogenesis. Cancer Lett. 2020; 474:15-22. DOI: 10.1016/j.canlet.2020.01.002. View

12.

Singh V, Yeoh B, Chassaing B, Xiao X, Saha P, Aguilera Olvera R . Dysregulated Microbial Fermentation of Soluble Fiber Induces Cholestatic Liver Cancer. Cell. 2018; 175(3):679-694.e22. PMC: 6232850. DOI: 10.1016/j.cell.2018.09.004. View

13.

Levy M, Thaiss C, Elinav E . Metagenomic cross-talk: the regulatory interplay between immunogenomics and the microbiome. Genome Med. 2015; 7:120. PMC: 4654884. DOI: 10.1186/s13073-015-0249-9. View

14.

Grat M, Wronka K, Krasnodebski M, Masior L, Lewandowski Z, Kosinska I . Profile of Gut Microbiota Associated With the Presence of Hepatocellular Cancer in Patients With Liver Cirrhosis. Transplant Proc. 2016; 48(5):1687-91. DOI: 10.1016/j.transproceed.2016.01.077. View

15.

Callahan B, McMurdie P, Holmes S . Exact sequence variants should replace operational taxonomic units in marker-gene data analysis. ISME J. 2017; 11(12):2639-2643. PMC: 5702726. DOI: 10.1038/ismej.2017.119. View

16.

DeSantis T, Hugenholtz P, Larsen N, Rojas M, Brodie E, Keller K . Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl Environ Microbiol. 2006; 72(7):5069-72. PMC: 1489311. DOI: 10.1128/AEM.03006-05. View

17.

De Matteis S, Ragusa A, Marisi G, De Domenico S, Casadei Gardini A, Bonafe M . Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities. Oxid Med Cell Longev. 2018; 2018:7512159. PMC: 6247426. DOI: 10.1155/2018/7512159. View

18.

Yu L, Schwabe R . The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol. 2017; 14(9):527-539. PMC: 6467288. DOI: 10.1038/nrgastro.2017.72. View

19.

Ikenaga N, Liu S, Sverdlov D, Yoshida S, Nasser I, Ke Q . A new Mdr2(-/-) mouse model of sclerosing cholangitis with rapid fibrosis progression, early-onset portal hypertension, and liver cancer. Am J Pathol. 2014; 185(2):325-34. DOI: 10.1016/j.ajpath.2014.10.013. View

20.

Loo T, Kamachi F, Watanabe Y, Yoshimoto S, Kanda H, Arai Y . Gut Microbiota Promotes Obesity-Associated Liver Cancer through PGE-Mediated Suppression of Antitumor Immunity. Cancer Discov. 2017; 7(5):522-538. DOI: 10.1158/2159-8290.CD-16-0932. View